Total Payments
$7,592
2024 Payments
$2,784
Companies
71
Transactions
307
Medicare Patients
1,656
Medicare Billing
$172,312
Payment Breakdown by Category
Food & Beverage$6,395 (84.2%)
Education$1,198 (15.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,395 | 291 | 84.2% |
| Education | $1,198 | 16 | 15.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $749.00 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $614.76 | 40 | $0 (2024) |
| PFIZER INC. | $396.24 | 16 | $0 (2024) |
| Gilead Sciences, Inc. | $362.45 | 18 | $0 (2024) |
| Genentech USA, Inc. | $326.68 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $295.31 | 13 | $0 (2024) |
| Seagen Inc. | $287.87 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $258.43 | 10 | $0 (2024) |
| GENZYME CORPORATION | $242.41 | 9 | $0 (2024) |
| Tempus AI, Inc | $230.56 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,784 | 123 | Novartis Pharmaceuticals Corporation ($268.59) |
| 2023 | $1,980 | 82 | Seagen Inc. ($271.73) |
| 2022 | $621.90 | 15 | Astellas Pharma US Inc ($266.31) |
| 2021 | $64.99 | 1 | Pharmacyclics LLC, An AbbVie Company ($64.99) |
| 2020 | $148.33 | 4 | Astellas Pharma US Inc ($65.67) |
| 2019 | $675.33 | 31 | Lilly USA, LLC ($100.00) |
| 2018 | $868.82 | 28 | Foundation Medicine, Inc. ($186.00) |
| 2017 | $449.41 | 23 | Novartis Pharmaceuticals Corporation ($99.89) |
All Payment Transactions
307 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.62 | General |
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Oncology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.53 | General |
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $0.55 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $31.15 | General |
| 11/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.78 | General |
| 11/25/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Genetically Defined Disease | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $9.55 | General |
| Category: ONC | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $110.19 | General |
| 11/18/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Oncology | ||||||
| 11/04/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: DESMOID TUMORS | ||||||
| 11/01/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $11.19 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.02 | General |
| 10/10/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $36.74 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 379 | 703 | $97,943 | $42,576 |
| 2022 | 5 | 387 | 691 | $97,434 | $42,645 |
| 2021 | 7 | 440 | 752 | $105,004 | $46,727 |
| 2020 | 7 | 450 | 797 | $109,840 | $40,364 |
Total Patients
1,656
Total Services
2,943
Medicare Billing
$172,312
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 241 | 407 | $44,821 | $18,481 | 41.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 86 | 244 | $39,040 | $17,682 | 45.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $7,750 | $3,548 | 45.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $4,000 | $1,673 | 41.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 11 | $2,332 | $1,192 | 51.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 234 | 384 | $42,240 | $17,326 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 85 | 238 | $38,080 | $17,215 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 32 | $6,784 | $3,600 | 53.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $5,580 | $2,467 | 44.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $4,750 | $2,037 | 42.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 248 | 417 | $45,870 | $19,791 | 43.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 86 | 226 | $36,160 | $16,728 | 46.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 36 | 36 | $9,000 | $3,765 | 41.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $6,510 | $3,098 | 47.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 19 | $4,028 | $2,221 | 55.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 14 | $1,764 | $739.18 | 41.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 17 | 19 | $1,672 | $384.98 | 23.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 259 | 425 | $46,750 | $16,193 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 89 | 268 | $42,880 | $16,187 | 37.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 32 | 32 | $8,000 | $3,131 | 39.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $4,960 | $2,041 | 41.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 18 | 18 | $3,816 | $1,523 | 39.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 15 | $1,890 | $831.28 | 44.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 21 | 23 | $1,544 | $457.10 | 29.6% |
About Dr. Timothy Cox, MD
Dr. Timothy Cox, MD is a Hematology & Oncology healthcare provider based in Petoskey, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437260650.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Cox, MD has received a total of $7,592 in payments from pharmaceutical and medical device companies, with $2,784 received in 2024. These payments were reported across 307 transactions from 71 companies. The most common payment nature is "Food and Beverage" ($6,395).
As a Medicare-enrolled provider, Cox has provided services to 1,656 Medicare beneficiaries, totaling 2,943 services with total Medicare billing of $172,312. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Petoskey, MI
- Active Since 08/31/2006
- Last Updated 11/27/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437260650
Products in Payments
- KISQALI (Drug) $309.82
- XTANDI (Drug) $297.38
- Trodelvy (Drug) $223.57
- KEYTRUDA (Biological) $207.67
- FOUNDATIONONE (Device) $201.19
- SIR-Spheres Microspheres (Device) $192.79
- Lenvima (Drug) $182.08
- VERZENIO (Drug) $159.83
- Erleada (Drug) $142.27
- RYBREVANT (Drug) $134.83
- ZOLADEX (Drug) $118.29
- SARCLISA (Biological) $103.95
- Da Vinci Surgical System (Device) $98.51
- REBLOZYL (Biological) $97.28
- OPDIVO (Biological) $87.51
- IMBRUVICA (Drug) $85.51
- GAZYVA (Biological) $73.07
- JAKAFI (Drug) $72.34
- BESREMI (Drug) $71.79
- SCEMBLIX (Drug) $68.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.